DBV Technologies : Better visibility – Buy vs Neutral
>One source of uncertainty fewer - Following the company’s refinancing, which gives it renewed confidence in terms of funding for the short term, we upgrade our rating to Buy vs Neutral. We had adopted a more conservative stance on DBV on 15 January (-5%) as a result of: i) a lack of regulatory visibility (little initial visibility on the re-filing of Viaskin Peanut); and also ii) the lack of financial visibility, despite an initial financing deal in April. The ...DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.